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ABSTRACT 
STUDY: 
 Study on the Prevalence of Metabolic syndrome in the Newly 
diagnosed Hypothyroid Patients. 
 
BACKGROUND 
 Metabolic Syndrome is common cause of Cardiovascular 
morbidity and mortality which is commonly associated with 
hypothyroidism Identification of metabolic syndrome in Hypothyroidism 
aids in early interventions. 
 
MATERIALS AND METHODS 
 
 This study included 100 members with 50 in Study group 
(Hypothyroid) and 50 in control group (Euthyroid) The screening for 
metabolic syndrome in study and control group is based on IDF criteria. 
15 among study group and 6 among control group had metabolic 
syndrome with significant p value < 0.05. 
 
 Among Lipid Profile Parameters Total Cholesterol, LDL, TG 
increased, and HDL decreased in study group compared to control group 
with significant P value < 0.05. 
 
RESULT 
 Metabolic syndrome is common in Hypothyroid than Euthyroid. 
Lipid profile parameters also had independent correlation with 
hypothyroidism. LDL, Total cholesterol, TG increased and HDL 
decreased in Hypothyroidism than Euthyroid state. 
 
KEYWORDS: 
 Metabolic syndrome, hypothyroidism, Euthyroidism, IDF Criteria, 
lipid profile, obesity Insulin resistance, Hypertension, CVD. 
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INTRODUCTION 
 Hypothyroidism is one of the most common endocrine disorders in 
the developing world 
 
 Hypothyroidism is a recognized risk factors for atherosclerotic 
cardiovascular disease, hyperlipidemia, low grade inflammation 
and hypercoagulability  
 
 Decreased thyroid function is associated with development of 
obesity and associated increased waist circumference that could 
potentially contribute to development of metabolic syndrome.  
 
  Lower thyroid function can increase peripheral vascular resistence 
and activate the sympatho-adrenal system leading to increase in 
BP, particularly DBP 
 
 Dysglycemia is more frequent among hypothyroid patients  
 
 Metabolic syndrome constitutes a cluster of risk factors 
characterized by hypertension, atherogenic dyslipidemia, 
hyperglycemia, prothrombotic and proinflammatory conditions.  
 
 Metabolic syndrome and its components are associated with higher 
risk of cardiovascular diseases.  
2 
 
  Metabolic syndrome and hypothyroidism are well established 
forerunners of atherogenic cardiovascular disease. Considerable 
overlap occurs in the pathogenic mechanisms of atherosclerotic 
cardiovascular disease by metabolic syndrome and 
hypothyroidism.  
 
 Hence I undertook this study to compare the prevalence of 
metabolic syndrome among hypothyroid  and euthyroid subjects 
and  to aid in early screening of metabolic syndrome  to prevent  
future complication 
 
  
  
 
AIMS  
AND  
OBJECTIVES 
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AIMS AND OBJECTIVES 
 
PRIMARY OBJECTIVE: 
To study the prevalence of metabolic syndrome in newly diagnosed  
hypothyroid patients.  
 
SECONDARY OBJECTIVE: 
To compare the prevalence of metabolic syndrome in newly 
diagnosed cases of hypothyroidism and euthyroidism, to aid in early 
screening and prevention of complications.  
 
  
  
 
REVIEW  
OF  
LITERATURE 
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REVIEW OF LITERATURE 
HISTORICAL REVIEW: 
The history of Metabolic syndrome rewinds around 250 years ago, 
before the term metabolic syndrome was coined up. It was the Italian 
anatomist and physician Morgagni who found the association between 
obesity, hypertension, atherosclerosis, uric acid disorders and sleep 
apnea. 
Nicole pauleseu stated that obesity with diabetes as consequent 
phases representing same pathology. Later Maranon in 1927 described 
AHT and obesity as pre-diabetic state. Thus in 1960’s simultaneous 
presence of DM, AHT, increased lipid levels and obesity was mentioned 
as pleurimetabolic syndrome.  
In 1980’s Reaven, an endorcrinologist identified the association of 
insulin resistance and compensatory hyper-insulinism with pathological 
process of each components and called it as X syndrome. Dr. Ferranini 
confirmed the association and named it as Insulin Resistence Syndrome. 
X plus syndrome in addition to X syndrome associated aging and 
hyperuricemia. Anthony ceami the biologist identified that the long 
standing elevated blood glucose as a main factor in the accumulation of 
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advanced glycosylation end products which ultimately led to accelerated 
aging by its interaction with protein and collagen at cellular level. 
The first definition of Metabolic syndrome was set by WHO in 
1998 later EGIR (European Group for the study of Insulin Resistance) 
brought alteration in WHO definition proposing insulin resistance as 
main cause. In 2001 NCEP- ATP III criteria came into existence for 
defining criteria for MS, which do not include insulin resistance. 
WHO criteria Table:                                         
Insulin resistance, identified by 1 of the following:  
• Type 2 diabetes    
• Impaired fasting glucose    
• Impaired glucose tolerance     
 • or for those with normal fasting glucose levels (<110 mg/dL), glucose uptake below  
   the lowest quartile for background population under investigation under  
   hyperinsulinemic, euglycemic conditions 
Plus any 2 of the following:  
• Antihypertensive medication and/or high blood pressure (≥140 mm Hg systolic or  
   ≥90 mm Hg diastolic)      
• Plasma triglycerides ≥150 mg/dL (≥1.7 mmol/L)     
 • HDL cholestero <35 mg/dL (<0.9 mmol/L) in men or <39 mg/dL (1.0 mmol/L) in  
    women 
 • BMI >30 kg/m2 and/or waist:hip ratio >0.9 in men, >0.85 in women  
• Urinary albumin excretion rate ≥20 µg/min or albumin:creatinine ratio ≥30 mg/g   
Derived from Alberti et al(57,58) 
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HYPOTHYROIDISM 
INCIDENCE OF HYPOTHYROIDISM: 
The incidence of hypothyroidism varies according to the 
population studied (1,2). Overt hypothyroidism is seen in about 0.3% of the 
population with elevated TSH levels and reduced freeT4 levels. 
Subclinical hypothyroidism is seen in about 4.3% of the population with 
elevated TSH levels with a normal freeT4 concentration. Subclinical 
hypothyroidism may progress to overt hypothyroidism. Incidence is more 
among women, elderly and some racial and ethnic groups(2). The 
incidence of Neonatal hypothyroidism is 1 in 3500 cases(3) 
INTRODUCTION 
                The name Thyroid is a greek word in which thyreos means 
shield and eidos means form. Thyroid gland consists of two lobes 
connected in between by isthmus. It is situated in between the cricoid 
cartilage and the suprasternal notch just anterior to the trachea. In its 
normal state, the gland weighs about 12 to 20 grams in size. Thyroid 
gland develops during third week of gestation from the floor of primitive 
pharynx and migrates along thyroglossal duct to the neck.  
Thyroxine (tetraiodothyronine or T4) and Triiodothyronine (T3) 
are the hormones principally secreted from the thyroid gland. They are 
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tyrosine based hormones responsible for the regulation of metabolism 
which is indeed more sensitive to minute changes in circulatory hormone 
level. Iodine is necessary for the production of thyroid hormones.T4 is 
the major form in blood and has a long half life than T3. T4 on 
deiodination can be converted to T3(  by  deiodinase) which is three to 
four times more active than T4. Ratio in blood is T4:T3 is 20 : 1 
approximately. Further processing by decarboxylation and deiodination 
produces iodothyronamine and thyronamine. Selenium is essential for T3 
production. 
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SYNTHESIS OF THYROID HORMONE 
1. Transport of iodide into follicular cells is against electrochemical 
gradient which is linked with Na-I transport. This requires energy 
from oxidation. The transporeter is located in the basolateral 
membrane of the follicular cells (4) 
 
2. Iodide then moves to apical side which is transported by iodide-
chloride transporter pendrin to the exocytotic vesicles where iodide 
is oxidise and then bound to tyrosyl residues. This reaction 
involves hydrogen peroxide. 
 
3. Two diiodotyrosine couples to form T4 and didiodo and 
monoiodotyrosine couples to form t3 which is also catalysed by 
peroxidise 
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4. Thyroglobulin is present in the lumen of  follicles (5) it is 
synthesised in the RER and then transferred to exocytotic vesicles 
in the apical cell membrane. The formation of thyroid hormones 
occurs in the region of specific amino acid sequence(6)      
 
5. The colloid which contains thyroglobulin is fused with tyrosine 
where it is hydrolyed and secreted into circulation. Recycling of 
iodide happens which is under control of gene that encodes 
iodotyrosidecleidonase (7). 
 
 
 
  
10 
 
PHYSIOLOGICAL EFFECTS OF THYROID HORMONES 
Thyroid hormone targets each and every cell of the body and has 
profound effects on development, growth and metabolism. 
DEVELOPMENT :   
The development of the fetal and neonatal brain requires normal 
levels of thyroid hormones. This was demonstrated by a classical 
experiment in which the tadpoles failed to develop into frogs when they 
were deprived of thyroid hormone 
GROWTH :   
There is an intimately interwined growth promoting effect between 
thyroid hormone and growth hormone, which is evidenced by growth 
retardation in thyroid disorders. 
METABOLISM:   
Thyroid hormone is involved in diverse metabolic activities 
leading to increased metabolic rate. 
Lipid metabolism  increased concentration of fatty acids in 
plasma due to fat mobilisation is seen in increased thyroid hormone 
levels. Oxidation of fatty acids is also enhanced. There is an inverse 
correlation between cholesterol and triglyceride levels and thyroid 
11 
 
hormone levels. Hypothyroidism is associated with increased blood 
cholesterol concentration. 
Carbohydrate metabolism Almost all aspects of carbohydrate 
metabolism are stimulated by thyroid hormones like Insulin dependent 
entry of glucose into the cells, gluconeogenesis , glycogenolysis to 
generate free glucose.    
PHYSIOLOGICAL EFFECTS OF THYROID HORMONE 
{ 
 
12 
 
OTHER EFFECTS:  
CVS Thyroid hormones increase heart rate, force of contraction 
and cardiac output. Promote vasodilation and enhances blood supply to 
many organs. 
CNS Decreased levels of thyroid hormones causes mental 
sluggishness and increased levels cause anxiety and nervousness. 
REPRODUCTIVE SYSTEM normal levels of thyroid hormones 
are essential for normal reproductive behaviour and physiology. 
Hypothyroidism is most commonly associated with infertility. 
CAUSES OF HYPOTHYROIDISM: 
Hypothyroidism is the clinical state featured by reduced production 
of thyroid hormone. The permanent loss thyroid gland,  by destruction 
due to radiation or autoimmune processes is called as primary 
hypothyroidism, which is the cause of 99% of hypothyroidism cases, and  
if such an impairment is progressive or transient then it will be typically 
associated with compensatory thyroid gland enlargement. Insufficient 
stimulation of the gland due to defect on hypothalamo or pituitary axis in 
producing thyroid stimulating hormone will result in central or secondary 
hypothyroidism 
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          The cause may be from hypothalamus, pituitary or from the gland 
itself. Primary hypothyroidism is due to defect in the thyroid gland which 
is the most common, amongst which autoimmune i.e ., Hashimoto 
thyroiditis (8) is more common, especially in elderly female. Auto 
antibodies mainly against peroxidise and iodide transporters is 
frequent(9,10) . High level of iodine intake is associated with subsequent 
increase in auto antibodies(11) 
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CAUSES OF HYPOTHYROIDISM: 
Primary  
Autoimmune hypothyroidism: Hashimoto's thyroiditis, atrophic thyroiditis 
Iatrogenic: 131I treatment, subtotal or total thyroidectomy, external irradiation of neck 
for lymphoma or cancer 
Drugs: iodine excess (including iodine-containing contrast media and amiodarone), 
lithium, antithyroid drugs, p-aminosalicylic acid, interferon- and other cytokines, 
aminoglutethimide, sunitinib 
Congenital hypothyroidism: absent or ectopic thyroid gland, dyshormonogenesis, 
TSH-R mutation 
Iodine deficiency 
Infiltrative disorders: amyloidosis, sarcoidosis, hemochromatosis, scleroderma, 
cystinosis, Riedel's thyroiditis 
Overexpression of type 3 deoiodinase in infantile hemangioma 
Transient  
Silent thyroiditis, including postpartum thyroiditis 
Subacute thyroiditis 
Withdrawal of thyroxine treatment in individuals with an intact thyroid 
After 131I treatment or subtotal thyroidectomy for Graves' disease 
Secondary  
Hypopituitarism: tumors, pituitary surgery or irradiation, infiltrative disorders, 
Sheehan's syndrome, trauma, genetic forms of combined pituitary hormone 
deficiencies 
Isolated TSH deficiency or inactivity 
Bexarotene treatment 
Hypothalamic disease: tumors, trauma, infiltrative disorders, idiopathic 
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Smoking is also associated with autoimmune thyroiditis(12)  
Iatrogenic causes like thyroid surgery, radio-iodine , radiation may lead to 
hypothyroidism. Iodine deficiency, medications and substances 
competing with iodine like lithium, thiocyanide, tyrosinekinase inhibitors, 
antithyroid drugs and also ethionamide (13) cause hypothyroidism. 
Postpartum thyroiditis may lead to transient hypothyroidism. 
Secondary and tertiary causes are due to tumour of pituitary mainly 
micro-adenoma, and  also sheehans syndrome, CNS trauma, infiltrative 
diseases and rarely resistence to T3 due to mutation of gene involving 
beta form of the nuclear receptor. Consumptive hypothyroidism due to 
increased breakdown of T3 T4 by T3 de-iodinase which is produced in 
ectopic site is also rare cause of hypothyroidism. 
CONGENITAL HYPOTHYROIDISM: 
Congenital hypothyroidism is one of the most preventable cause of 
mental retardation where exist inverse relation between age of diagnosis 
and beginning of treatment (14).  Earlier screening was done by heel stick 
blood (15). It has male to female ratio of 2: 1 mainly due to ectopic thyroid 
than thyroid agenesis(16). 
Most common cause is sporadic 85% and rest is hereditary due to 
inborn errors of synthesis. Central hypothyroidism in infants also had 
 other pituitary hormone insufficiency mainly to be doubted 
with low blood sugar and micropenis. Inadequate treatment of maternal 
graves disease is also a cause if it is before 32 w
life(17).  
Transient hypothyroididsm in infants is due toiodine deficiency in 
mother and also due to 
treatment and other drugs like amiodarone 
(21,22)
. Large hemangiomas of liver producing type 3 deiodinase mutation 
in DUOX1 &DUOX2 gene are also rare causes. 
16 
eeks of intrauterine 
blocking antibodies(18,19) maternal antithyroid 
(20)
 , radiographic contrast 
 
in infants 
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The clinical features manifested are increased birth weight than 
birth length, increased head circumference, decreased calcification of 
knee hypophysis, lethargy, feeding difficulties and macroglossia etc. 
associated malformation of heart, kidney, GIT, skeletal system is also 
prevalent in congenital hypothyroidism (23-27). Infants with positive 
screening are further tested for TSH, free T3, T4 so confirm 
hypothyroidism which is followed by radionucleotide imaging, USG, 
urine iodine and autoantibodies to rule out the cause. 
HYPOTHYROIDISM IN PREGNANCY: 
The most common cause of hypothyroidism in pregnancy is 
Autoimmune thyroiditis. Hypothyroidism in subclinical state is usually 
assymptomatic. There is miscarriage risk (28) attributed to autoimmune 
thyroiditis. Even euthyroid antenatal women autoantibodies are at risk of 
miscarriage. So they are also treated with thyroxine(30)  i.e like subclinical 
hypothyroid dose. Overt hypothyroidism is also associated with risk of 
diabetes. 
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The presence of thyroglobulin in the amniotic fluid suggests the 
transfer of the hormone from mother to fetus which inturn is essential for 
development of the central nervous system of the fetus.  It also protects 
the fetus from respiratory distress. There is increased risk of maternal 
diabetes, hypertension, abortion and postpartum hemorrhage in maternal 
hypothyroidism. 
19 
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  CLINICAL FEATURES OF HYPOTHYROIDISM: 
SIGNS AND SYMPTOMS OF HYPOTHYROIDISM  
(DESCENDING ORDER OF FREQUENCY) 
 
Symptoms 
    Tiredness, weakness 
    Dry skin 
    Feeling cold 
    Hair loss 
    Difficulty concentrating and poor  
     memory 
    Constipation 
    Weight gain with poor appetite 
    Dyspnea 
    Hoarse voice 
    Menorrhagia (later oligomenorrhea  
     or amenorrhea) 
    Paresthesia 
    Impaired hearing 
Signs 
    Dry coarse skin; cool peripheral  
    extremities 
    Puffy face, hands, and feet  
    (myxedema) 
    Diffuse alopecia 
    Bradycardia 
    Peripheral edema 
    Delayed tendon reflex relaxation 
    Carpal tunnel syndrome 
    Serous cavity effusions 
 
 
Clinical signs of hypothyroidism occurs due to absence of 
transcription of genes encoding calcium ATPase (Brent 1994) leading to 
prolonged relaxation and it also mobilises monopolysaccharides which is 
abnormally deposited in hypothyroidism. It also alters responsiveness of  
reticular activating system to catecholamines, alters the fluid and 
electrolytes homeostasis and also changes in blood flow.(beauretal 2008) 
The clinical manifestations are as shown in the table. Patients with very 
severe disease have very cold doughy skin, macroglossia, periorbital 
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puffiness, cardiomegaly and paralytic ileus. Most serious (jorden 1995) 
and rare complication of severe hypothyroidism is myxedema especially 
in elderly women with. It presents with decreased level of consciousness, 
decreased heart rate, decreased respiratory rate. Seizures may even occur 
due to altered metabolic parameters like hypoglycaemia and 
hyponatremia. 
Another rare presentation is Hashimotos encephalopathy which can 
present as tremor opsoclonus myoclonus convulsion (chonj et al 2003, 
Castillo et al 2006). The people with hypothyroidism may also present 
with headache, bradykinesia, ataxia, even hearing loss, muscle weakness 
and sleep disorders like obstructive sleep apnea in patients with 
subclinical hypothyroidism 
DIAGNOSIS OF HYPOTHYROIDISM: 
 Both clinical and lab inveastigations play a key role in diagnosis of 
hypothyroidism. Level of Thyroid stimulating hormone in subclinnial 
hypothyroidism is the key marker of dysfunction in euthyroid patients. 
T4, Antithyroid microsomal antibody testing as their presence indicating 
damage to thyroid gland causing hypothyroidism known as hashimotos 
thyroididtis. But these patients may initially present as hyperthyroidism 
due to release of stored thyroid hormones 
 22 
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METABOLIC SYNDROME 
INTRODUCTION : 
Metabolic syndrome is combination of metabolic abnormalities 
described in 1920 by kylin, in which he included hypertension, gout and 
diabetes. Then Vague observed upper body obesity associated with 
hyperglycemia and heart disease. Banting and Rever then named it as 
Syndrome- X though obesity is not included in it. Now metabolic 
syndrome is the most widely used terminology. 
DEFINITION: 
                Recently WHO, Adult Treatment Panel III, NCEP ATP III  and 
EGIR has framed definition for Metabolic syndrome all of which 
included BP, Abnormal lipid profile, Insulin resistance, and Obesity but 
the criterias are different. WHO insists on insulin resistance as major 
factor in metabolic syndrome. So elevated blood sugar in the form of 
impaired glucose tolerance is important for metabolic syndrome to be 
diagnosed. Along with this two more factors are needed.  
 EGIR definition has its utility more in epidemiological studies as it 
does not need euglycemic clamp for testing insulin sensitivity. So it is 
feasible in larger studies. It used Fasting blood sugar and also there is 
 change in cutoff range in hypertension, hi
waist circumference range and triglyceride levels
COMPARISION TABLE OF METABOLIC SYNDROME: 
ATP III:  
             It was actually proposed as a programme for presenting heart 
diseases which mostly involved obesity as a key factor. Now AACF has 
included fasting and post 
diagnosis of metabolic syndrome
simple definition as a tool for identification for risk in clinical practice
24 
gh density lipopretein
 
-prandial blood sugar level in 
. Since there is an imminent need for 
 level, 
 
 
the criteria for 
. 
                  Central obesity is calculated by waist circumference using 
guidelines set for gender and various ethnic groups. Here the cutoff points 
are based on the ethinicity not on the basis of where the people is actually 
residing. This is to be used in epidemiological studies which involve large 
study population and various ethnic group
ADDITIONAL METABOLIC PARAMETERS UNDER 
RESEARCH 
                  There are other factors that appear to be associated in 
metabolic syndrome which are to be utilised in forthcoming research 
studies as they improvise the predictabily of risk involved in c
diseases and diabetes. These additional parameters thereby alter the 
definition leading to new set of criterias for better assessment of risk 
factors.  
25 
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ardiac 
 Definitions of MBS for women, according to WHo, NCEP ATP III and IDF Criteria
INTRODUCTION
Metabolic syndrome comprise of components as follows:
• BP 
• DM 
• HYPERCHOLESTEROLEMIA
• OBESITY
• INSULIN RESISTENCE
          The distribution of these parameters includes elevated cholesterol, 
elevated BMI, as most commonly involved metabolic parameters. These 
parameters are followed by other parameters like HBA1C, increased 
blood sugar, albuminuria, which are less common. Increased risk of 
cardiovascular disease is mainly influenced by elevation of blood glucose 
and occurrence of proteinuria which pose greatest t
of cardiovascular disease
levels exist as the most common parameter in combination components.      
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hreat for development 
. Amongst all these risk factors higher lipid 
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PATHOPHYSIOLOGY OF METABOLIC SYNDROME: 
•  Adipose tissue releases FFA which causes high glucose, TGs and 
VLDL, associated with high LDL and low HDL. 
 
• FFA also decrease sensitivity of insulin in muscle, leading to 
inhibition of glucose uptake which is insulin mediated. 
 
• Increased free glucose in circulation increases insulin release from 
pancreas causing hyperinsulinemia leading to high Na+ absorption 
and SNS activity causing hypertension 
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OBESITY: 
              Among different type of diabetes mellitus, the relationship of  
obesity is complex as we some diabetic patients with lean stature. Obesity 
is forerunner of diabetes due to insulin resistence (31,32) . The reason for 
obesity varies in different types amongst which genetic disposition is 
most clearly involved (49,50,51) so decreasing obesity is the main stay of 
treatment. 
 PATHOPHYSIOLOGY OF
FFA is the main source of energy to skeletal muscle kidney and 
liver. It is the main source of triglyceride production for liver. During 
starvation it provides alternate s
to increased oxidative stress during its utility as energy source leading to 
metabolic syndrome
triacylglycerol is decreased due to hyper
liberation of endothelial lipoprotein lipase which ultimately ends in 
insulin receptor dysfunction. Resistance to insulin increases the 
generation of glucose from live r and increase free fatty acid leads to 
decreased utility of glucose exaggerating 
more(35,36) 
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 OBESITY : 
ource to glucose. The free fatty acid leads 
(33,34)
. As lipogenesis is inhibited clearance of 
-triglyceridemia. This lea
the hyperglycemia even 
 
ds to 
 Adipocytes release adipokines namely lectin, vistatin, nectin, 
which along with insulin regulates fat mass in the body
proteo-homones but also inflammatory adipokines like cytokines, TNF 
alpha, interleukin 1,6 are released, so increased fat content as in obesity 
leads to increased co
resistence, non alcoholic steato
cells decreasing the secretion of insulin. This is cou
inflammatory adipokines like leptin and resistin which leads to 
atherogenic tendency.
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-morbid conditions like type 2 DM
-hepatitis and injury to pancreatic beta 
nter balanced by anti 
 
 
 
(37,38)
, not only 
(39)
, insulin 
 CLINICAL MANIFESTATIONS OF OBESITY:
Obesity leasds to co
increased blood pressure, atherogenesis, non
obstructive sleep apnea. In all these cases inflammatory  mediators leads 
to altered immune response. Obesity is also a risk factor for carcinoma 
colon as it involves apoptosis, inflammation, cellular proliferation along 
with gene expression and toxins. Men with high BMI had increased death 
rate in carcinoma prostate when compared with men having normal 
BMI(40) 
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-morbidities like type2 DM, dyslipidemis, 
-alcoholic steato-hepatitis, 
 
 CARCINOMA AND OBESITY:
 Hepatocellular carcinoma is associated with obesity since fatty 
liver in obesity can progress 
carcinoma liver. Leptin is also a risk factor leading to increased growth of 
carcinomas(41) .   
 
              The inflammatory adipokines increases blood sugar and  
Hyperinsulinemia along with inflammatory media
inflammation and dysfunction. Pancreatic dysplasia which occurs due to 
chronic inflammation in cases of chronic pancreatitis may promote the 
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to cirrhosis which inturn may be risk for 
tors cause beta cell 
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development of adenocarcinoma of pancreas(42,49) .Adiponectin which is a 
adipokine secretogogue prevents angiogenesis. But in obesity there is 
decreased level of adiponectin when compared to proinflammatory 
adipokines promoting carcinoma(43,44). Oestrogen is also associated with 
cancer of breast,prostate and ovary. Genes have key role in the cancer 
along with the above mentioned risk factors. 
 OBESITY AND GALL STONE: 
                In obesity, increased removal of cholesterol during fasting 
increases the secretion of cholesterol into bile leading to gall stone 
development(47). These gall stones when chronically present can induce 
inflammation leading to risk of development of gall bladder cancer. 
OBESITY AND JOINT DISEASE:  
Joint disease are exaggerated in obesity due to the inflammatory 
mediators like resistin(45,46)  and weight bearing.  
RESPIRATORY SYSTEM AND OBESITY: 
                Obese persons are more prone for diseases of respiratory 
system. Obesity leads to increased deposition of fat in the upper 
respiratory tract leading to obstructive sleep apnea. It may also lead to 
hyoxia and even increased carbondioxide retension. In the region of 
bronchus these adipose tissue release inflammatory adipokines resulting 
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in asthma. Patients who were in prolonged state of deceased mobility are 
at higher risk of pulmonary embolism especially when they are obese(48) 
 OBESITY-RELATED ORGAN SYSTEMS REVIEW 
 
Cardiovascular  Respiratory  
  Hypertension   Dyspnea 
  Congestive heart failure   Obstructive sleep apnea 
  Cor pulmonale   Hypoventilation syndrome 
  Varicose veins   Pickwickian syndrome 
  Pulmonary embolism   Asthma 
  Coronary artery disease Gastrointestinal  
Endocrine    Gastroesophageal reflux disease 
  Metabolic syndrome   Nonalcoholic fatty liver disease 
  Type 2 diabetes   Cholelithiasis 
  Dyslipidemia   Hernias 
  Polycystic ovarian syndrome   Colon cancer 
Musculoskeletal  Genitourinary  
  Hyperuricemia and gout   Urinary stress incontinence 
  Immobility   Obesity-related glomerulopathy 
  Osteoarthritis (knees and hips)   Hypogonadism (male) 
  Low back pain   Breast and uterine cancer 
  Carpal tunnel syndrome   Pregnancy complications 
Psychological  Neurologic  
  Depression/low self-esteem   Stroke 
  Body image disturbance    Idiopathicintracranial hypertension 
  Social stigmatization   Meralgia paresthetica 
Integument    Dementia 
  Striae distensae   
  Stasis pigmentation of legs   
  Lymphedema   
  Cellulitis   
  Intertrigo, carbuncles   
  Acanthosis nigricans   
  Acrochordon (skin tags)   
  Hidradenitis suppurativa   
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OBESITY AND PRE-ECLAMPSIA: 
Obesity is also risk factor for pre-eclampsia  as these inflammatory 
adipokines include derivatives of substance like prostaglandins, RAS 
which are involved in the development of pre-ecclampsia .   
 
                Obesity is a key factor in polycystic ovarian syndrome in which 
the secretogogues released from adipose tissue leads to metabolic 
derangements. Apart from pre-eclampsia, PCOS, hypertension and 
obesity may also cause depression, urinary stress incontinence, 
amenorrhea and poor wound healing. Most of the disorders can improve 
with reduction of BMI.  
 MANAGEMENT OF OBESITY:
 
Treatment 
Diet, exercise, 
behavior therapy 
Pharmacotherapy 
Surgery 
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A Guide to Selecting Treatment 
BMI 
Category   
25–26.9 27–29.9 30–35 
With 
comorbidities 
With 
comorbidities + 
With 
comorbidities  + 
   
comorbidities
 
  
35–39.9 40 
+ + 
+ + 
With 
 
+ 
 
 FUNCTIONS OF INSULIN:
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INSULIN RESISTENCE 
INTRODUCTION: 
Earlier it was widely accepted that diabetes was mainly due to 
deficiency of insulin secretion. Later after ten years of discovery of the 
hormone in 1922 by Banting and Best, it was proposed that it is insulin 
resistance  and not the deficiency which leads to type 2 diabetes. Berson 
together with Yalow demonstrated that people with type 2 diabetes had 
higher levels if insulin, which was later corroborated by Roth(52) and 
Reaven(53,54) 
PATHOPHYSIOLOGY: 
The pathogenesis of insulin resistance  is defect in metabolism 
involving muscles fat liver and beta cell of pancreas. Insulin resistance 
has genetic predisposition which is further fuelled by obesity. When the 
beta cells are not able to compensate for insulin resistance then glucose 
tolerance occurs. Increased fatty acid generation by adipose tissue and 
increased glucose production by liver accompanied with failure of beta 
cell to produce insulin leads to exogenous insulin requirement. 
Insulin resistance apart from type2 DM  is the source of risk in 
other disease states like coagulation disorder, abnormal lipid profile, 
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weight gain hypertension, atherosclerosis,  PCOD, together known a 
Syndrome-X(55) 
 
  
MECHANISM OF INSULIN RESISTANCE 
Primary abnormality leading to insulin resistance is the defect in 
transport of glucose into the skeletal muscle. Defect in insulin receptor 
phosphorylation and subsequent phosphotidyl inositol 3 kinase action by 
fatty acid leads to defective glucose transport across the skeletal muscle. 
Understanding the underlying defects leading to insulin insensitivity will 
pave way for identification of newer therapeutic targets. 
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The fact of insulin resistance leading to type II  DM is supported by  
(i) Offsprings of patients with typeII DM having insulin insensitivity   
(ii) Prevention of  hyperglycemia  by agents which sensitize insulin. 
Nowadays there is a shift from glucocentric view to lipocentric 
view of insulin resistance. Ectopic deposition of lipid contributes to 
insulin sensitivity which is known as lipotoxicity. Derangement in the 
metabolism of fatty acid leads to abnormal deposition of lipid causing 
insulin resistance. Though indices like BMI ,waist circumference, waist/ 
hip ratio, measurement of lipids inside the muscle cells by MR 
Spectroscopy  is the one which associates insulin resistance more closely 
to obesity(56) 
In lipodystrophy there is limited availability of lipid storage depot 
and decreased leptin  leading to overeating. In lipotoxicity there is surplus 
lipid. Replacing adipose tissue in lipodystrophy leads to decrease in 
intake of energy and insulin sensitivity.  
MUSCLE GLUCOSE METABOLISM IN INSULIN RESISTANCE:  
13C MRS is a novel method to measure intramuscular glucose 
level. Through this study, it is observed that in normal people  80% of 
glucose uptake is converted to glycogen and stored in muscle as a source 
of glucose to be used when needed. The two organs which store glucose 
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in the form of glycogen is muscle and the liver. So in diabetes  stored 
level of glycogen in these organ is reduced. So utility of this method is to 
detect the rate limiting aspect in diabetogenesis  responsible for defect in 
storage of glucose as glycogen. 
31P MRS and 13C MRS were used to measure concentration of 
glycogen and glucose 6P. This is done in the state of hyperglycemia and 
hyperinsulinemia phase. G6P is intermediate and its phosphorylation by 
the enzyme hexokinase which leads to subsequent glycogen formation. In 
this method  it was observed that there is increase in concentration of 
glucose 6P. 
In diabetes the concentration of G6P inside is less, indicating that 
either glucose transport inside the muscle or its phosphorylation are the 
steps which control the rate. The same is observed in the offsprings of the 
patients with type2 DM who were resistant to insulin. Now in order to 
identify either glucose transport or its phosphorylation is defective. 
13CMRS method is used to measure free glucose level inside the muscle. 
It was found that intracellular glucose level in skeletal muscle is low 
indicating it is the transport of glucose that is rate controlling for 
synthesis of muscle glycogen by stimulation of insulin in type 2 DM 
patients. 
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LIPID MEDIATED RESISTANCE TO INSULIN  
It was found that infusion of lipids to elevate the concentration of 
fatty acids led to reduced disposal of insulin mediated glucose transport. 
But decrement in sensitivity of insulin happened only several hours after 
the increase in concentration of fatty acid . This delay in sensitivity of 
insulin is because of increase in oxidation of fatty acid would lead to 
increase in NADH : NAD ratio. This leads to inactivation of the enzyme 
pyruvate dehydrogenase, this inturn led to elevated levels of intracellular 
citrate. The citrate elevation inhibits the enzyme phosphofructokinase. 
This is followed by accumulation of G6P.  As the G6P inhibits the 
activity of enzyme hexokinase there is increased accumulation of glucose 
inside the cell there by leading to decreased  uptake of glucose by muscle 
cells. 
In type 2 DM there is decrease in level of intracellular G6P rather 
than elevated level as described by the hypothesis. This lead to the 
possibility of alteration in the activity of trafficking of insulin mediated 
GLUT4 in between the inside of cell and cell membrane. The fact 
observed was that insulin receptor substrste -1 (IRS-1) associated P13 
kinase action was decreased to significant extent under the condition of 
lipid infusion . So it may be the increased fatty acylCOA or other 
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derivatives of fatty acid inside the liver and muslce can cause resistance 
of insulin based on more delivery or decreased metabolism of  glucose.   
 
INFLAMMATION AND INSULIN RESISTANCE: 
Apart from adipokines proinflammatory TNF alpha secreted by 
monocytes  affects the coagulation profile and function of endothelium.  
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There is decreased expression of IRS and gene of GLUT4 leading 
to reduced uptake of insulin dependent glucose (59). Genes like HSL 
ADIPOQ and nuclear receptors like RXR and the PPAR- g are 
responsible for the maintaining of glucose homeostasis. The altered 
expression of the above mentioned genes by change in the expression of 
adipocytes led to insulin insensitivity . Salicylates repress Ikkb leading to 
protection from resistence to insulin in obesity.  LISR  produced by liver 
presents lkkb activation protecting hepatic resistance to insulin. The 
activation of genes that codes iNOS lead to increased resistance to  
insulin (60).   
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Insulin resistance in patients with sepsis is mediated by iNOS  
s- nitrosylation of  IRS and Akt (61,62). IL-10, the anti inflammatory agent 
produced by leukocytes is used in treatment of resistance to insulin.  
          The down regulation of genes encoding macrophage expression 
also helps in increasing sensitivity to insulin. 
 Thiazolidinediones used in insulin resistance is based on this 
mechanism(63). Cognate receptor, chemokine receptor -2 and monocyte 
chemoattractant protein-1(MCP) which induced the movement of 
monocytes to the tissues which were inflammed lead to increased insulin 
sensitivity.  
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DYSLIPIDEMIA IN METABOLIC SYNDROME: 
                In dyslipidemia increased formation of VLDL ApoB100 and 
their decreased catabolism and increased HDL degradation leads to 
metabolic syndrome.      
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  The insufficient esterification of free fatty acids and increased 
resistance to insulin both can lead to increased fatty acids to liver leading 
to increased VLDL ApoB and increased clearance of  HDL. The liver 
obtains more FA from circulation which induces triglyceride synthesis 
which leads to increased VLDL and increased ApoB formation from liver 
. In case of insulin resistance more insulin is present, in such a 
circumstance the inhibitory effect of insulin on secretion of VLDL is 
reduced. 
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In the state of insulin resistance the LDL level is not affected much 
but the composition of LDL is altered in such a way it is small and more 
dense. This is because of increased triglyceride level. Increased 
triglyceride levels also leads to decreased HDL because cholesterol 
depleted HDL is more susceptible for destruction. In person with 
metabolic syndrome though fasting TG level is low, after food intake the 
transient rise of TGs can lead to the same process as above. 
MANAGEMENT OF DYSLIPIDEMIA IN METS: 
Niacin is of more significance in the treatment of most of the 
common abnormalities of lipids in metabolic syndrome. Niacin acts by 
decreasing  lipolysis from adipose cells there by reducing the level of free 
fatty acid. This inturn leads to decreased availability of free fatty acids to 
liver. The binding of niacin to its receptor reduces cAMP which inturn 
inhibits lipolysis. However there is rebound elevation of  FFA level. 
Niacin increases HDL level by ATP binding cassette AI- mediated 
transport of cholesterol.   
 
  
Fibrates elevate HDL level by increased expression of Apo AI &II. 
The fibrates also has TG lowering action which is responsible for 
reducing LDL levels. Nowadays combination therapy is considered safe 
inspite of myopathy and rhabdomyolysis as a common adverse effect.
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METABOLIC SYNDROME AND HYPERTENSION 
Hypertension in metabolic syndrome is closely linked to 
dysfunction of vascular system which plays the key role in Mets. The 
classical pathway releasing NO is different from the pathway through 
which insulin releases NO. Insulin resistant state is favourable to 
vasoconstrictor tone. The adipose tissue present around the vascular 
system, through the secretion of adipokines alter the tone by its 
vasoactive property. 
       BLOOD PRESSURE CLASSIFICATION 
 
Blood Pressure 
Classification 
Systolic, 
mmHg 
Diastolic, 
mmHg 
Normal <120 and <80 
Prehypertension 120–139 or 80–89 
Stage 1 hypertension 140–159 or 90–99 
Stage 2 hypertension 160 or 100 
Isolated systolic 
hypertension 
140 and <90 
 
 
INTRODUCTION: 
               Since type2 DM has its effect more on vascular system, it is 
called as cardiometabolic  syndrome. In 20th century, the physicians 
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identified that hypertension and diabetes occurred due to common 
mechanism(64) 
 ROLE OF SYMPATHETIC NERVOUS SYSTEM: 
                 The increased levels of insulin, leptin and lipids cause 
exaggeration of sympathetic tone. 
 
Among these hyper-insulinemia irrespective of changes in blood 
sugar level cause elevation of circulatory Nor-adrenaline. This is 
subsequently accompanied by elevation of blood pressure. Moreover this 
type of response to hyperinsulinema is centrally mediated as local 
infusion does not produce this response(65). Increased insulin level also 
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favours sodium reabsorption predisposing to hypertension. Obese persons 
need more arterial pressure to maintain sodium homeostasis leading to 
impaired pressure natriuresis.(64) 
Leptin apart from its effect on appetite also activates sympathetic 
nervous system through the hypothalamus resulting in hypertension. This 
action is mediated through ventro , dorso medial nucleus of 
hypothalamus(66)  
 
               Finally higher levels of FFA in circulation of visceral obese 
patients leads to sympathetic system activation.  
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INSULIN RESISTANCE AND ENDOTHELIAL DYSFUNCTION 
Himsworth’s work in 1939 postulated that type II DM is insulin 
resistance state more than the deficiency of insulin. The mechanism 
through which insulin resistance causing dysfunction of endothelium is 
complex which involves inflammatory mediators from adipose tissue 
muscle and liver. The insulin resistance is in favour of endothelin -1 due 
to impairment of synthesis of NO leading to vasoconstriction 
 
ROLE OF NO IN INSULIN RESISTANCE 
In 1985 King identified the expression of insulin receptors in 
endothelial cells, as a physiological response insulin elicits NO mediated 
increase in flow of blood, through the capillary recruitment. Thereby 
insulin resistance leads to diminished NO synthase action. There is 
abnormality in basal action of NO mediated dilation (67). Insulin induces 
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the release of NO synthase through a pathway different from the classical 
one which involves calcium dependent G protein coupled receptor like 
Ach receptor. 
 
ROLE OF ENDOTHELIN -1 IN INSULIN RESISTANCE: 
             Oliver demonstrated the ability of insulin in stimulating 
endothelin-1 gene expression on the endothelium. There is alteration of  
levels of endothelin-1 in type 2 DM . Insulin has action on both NO 
mediated vasodilation and ET-1 mediateed vasoconstriction. Also 
endothelin -1 release leads to insulin resistance through the reduction of 
skeletal muscle blood supply and also decreases NO, increases oxidative 
stress thereby leading to pro-atherogenic state.  
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HYPERGLYCEMIA AND VASCULAR FUNCTION 
Acute hyperglycemia in healthy individuals leads to impaired 
vasodilation both  in micro and macro circulation. Insulin down regulates 
the stimulation of L-arginine transporter which also elevates NO and 
prostacyclin release in hyperglycaemic state which is unfavourable. The 
insulin mediated vasodilation doesnot occur in the presence of 
hyperglycemia added by vasoconstrictor effect of glucose per se.(68) 
INSULIN ACTION ON BLOOD PRESSURE: 
Insulin has both local and systemic effects on cardiovascular 
system. The systemic effect is that it affects renal and sympathetic 
nervous system. The insulin resistance resulting in compensatory 
hyperinsulinemia leads to increased reabsorption of sodium and 
sympathetic activity both of which results in hypertension. Individuals 
with primary hypertension who are lean also exhibits insulin resistance 
and hyperinsulinemia.  
              The drugs which are used in trestment of insulin resistance also 
has anti hypertensive action. For example, oral metformin used for the 
treatment of insulin resistance resulted in significant reduction in arterial 
pressure. One more example is the antihypertensive glitazone also 
improved insulin sensitivity.  
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ROLE OF ADIPOKINES: 
The adipocytes are reservoirs of energy that store in fed state and 
liberates FFA in fasting state. Apart from this adipocyte also does 
endocrine function of secreting adipokines the substance synthesised and 
released from adipocytes. Main source of inflammatory adipokines is the 
visceral fat accumulation  which plays pivotal role in the development of 
cardiovascular disease and other disorders in the spectrum of metabolic 
syndrome.    
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PERIVASCULAR ADIPOSE TISSUE AND VASCULAR 
DYSFUNCTION 
Adipose tissue as an endocrine organ has significant implication in 
knowing the pathophysiological relationship of fat and elevated blood 
pressure. Most of the arteries are surrounded by fat layer known as 
perivascular adipose tissue. Saltis described certain action of PVAT on 
contractility of vessels. PVAT promotes vasoconstriction when 
electrically stimulated (69) and due to reactive oxygen species produced by 
NADPH Oxidase which impairs endothelial function. The 
anticontractility of ADRF (ADVENTITIUM DERIVED RELAXING 
FACTOR) is through opening of K+ channels present in the smooth 
muscle of vessels.(70), 
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METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE 
Inspite of uncertainities of link between obesity and coronary heart 
disease, AHA has observed obesity as risk factor for CHD. This is of 
significance in the prevention and management of coronary heart disease.  
27th Bethesda conference identified obesity as class II risk factor that is 
the reduction of obesity leads to significant reduction in incidence of 
CHD. Though there is significant epidemiological evidence of correlation 
between obesity and heart disease the data based on clinical trials are not 
sufficient. Univariate analysis has observed linear relationship between 
obesity and CHD. But datas are less favourable in case of multivariate 
analysis. 
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MECHANISM OF RISK 
              The CHD risk is multifactorial and the risk factors can either be 
primary   Eg LDL cholesterol or may be facilitatory like hypertension, 
smoking, obesity and type II Diabetes mellitus. The metabolic parameters 
associated with obesity contributing to cardiovascular disease risk are 
 
• Insulin resistance 
• Type II Diabetes Mellitus 
• Abnormal lipid profile 
• Systolic and Diastolic Hypertension 
• Sympathetic nervous system dysfunction 
• Left ventricular hypertrophy 
• Obstructive sleep apnoea 
 
          Persons having metabolic syndrome are at three fold higher risk of 
CVD. Obesity is associated with high end diastolic volume due to volume 
overload. This along with elevated blood pressure lead to LVH.The LVH 
is associated with increased risk of arrhythmia ,sudden cardiac death and 
heart failure. 
  
 HEART FAILURE AND OBESITY
                There is also significant relationship between obesity and heart 
failure.The heart failure risk increased  two folds with BMI>30Kg
when compared with individuals who are not
for men increased 5% and
increase in BMI. The overweight women had increased risk but not in 
overweight men. But after developing heart failure the increased BMI 
lead to low rehospitalisatio
ECG CHANGES  IN OBESITY:
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 obese. The heart failure risk 
 women increased 7%with each 1kg/m2
n rates and decreased mortality.
 
 /m2 
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IDENTIFICATION  OF  PATIENTS  AT  RISK  OF  METABOLIC 
SYNDROME 
            The assessment of risk includes Blood Pressure, Waist 
circumference, Fasting glucose and lipid profile. The Endocrine society 
guidelines suggest evaluation every three years for people with one or 
more risk factors.(64). 
Assessment of risk factor for CVD can be done using 
FRAMMINGHAM  RISK SCORE. 
The risk of type II DM is higher with persons having other 
components of Metabolic syndrome. 
The risk of CVD in Metabolic syndrome is significantly related to 
Insulin resistance found in Metabolic syndrome than with obesity 
alone.CVD risk can be obtained by ECG, Carotid  Doppler, Ankle  
Brachial blood pressure can be related to Metabolic syndrome. 
Other disorders associated with Metabolic syndrome are Fatty 
Liver, Cirrhosis, CA Liver, Cholangio carcinoma, CKD, OSA, 
Hyperuricemia, gout Cognitive dysfunction to the extent of Dementia. 
CLINICAL DIAGNOSIS OF METABOLIC SYNDROME 
From clinical aspect Metabolic syndrome can be identified by 
simple criterias. 
  
FRAMMINGHAM  RISK SCORE:
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RISK ASSESSMENT 
 Many studies have concluded that middle age group with metabolic 
syndrome are more at absolute risk of ASCVD  in ten years. Even in 
young adults long term risk is high for ASCVD. The factor which is more 
contributing to increased ASCVD risk is premature diabetes mellitus. 
 In order to reduce the risk of ASCVD, persons with metabolic 
syndrome need long term management and follow up. The main aim is to 
decrease the risk factor. Individuals having ASCVD or Diabetes are in 
high risk state. People without ASCVD or Diabetes, risk is based on 
FRAMINGHAM RISK SCORE. This estimates CHD risk of 10 years. 
 
TYPE II DIABETES MELLITUS 
The existence of diabetes along with other risk factors favours 
higher risk which can be predicted by IFG or IGT. People with elevated 
IFG or I GT is termed as prediabetic state.IGT is more useful in 
uncovering the risk of development of Diabetes than IFG. So in order to 
decrease the need of OGTT, ADA decreased the threshold IGF from 
earlier 110 mg/dl to100mg/dl.So these individuals need lifestyle 
modification to delay the  progression to TYPE II Diabetes mellitus. 
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MANAGEMENT OFUNDERLYING RISK FACTOR 
           Though many individuals are prone to metabolic syndrome they 
are not clinically manifested in the absence of obesity and sedentary 
lifestyle. 
 
ABDOMINAL OBESITY 
First priority in abdominal obesity and metabolic syndrome is weight 
reduction which can be achieved by 
(i) Physical inactivity 
(ii) Decreased calorie intake 
(iii) Behaviour change 
The achievement of weight loss is to 7 to 10%of  baseline body 
weight in 6 to 12 months. This can be achieved by reducing calorie intake 
approximately 500 to 1000 calories per day. 
Drugs for weight loss has limited utility in the management of 
obesity due to adverse effects. Bariatric surgery is increasingly indicated 
for severe obesity but has its own disadvantages. 
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PHYSICAL INACTIVITY 
Increasing physical activity reduces the overall metabolic risk and 
more importantly ASCVD Risk. More than 30 minutes of  brisk walking 
for 5 days preferably all days of the week. 60 mins of continuous or 
intermittent aerobic exercise can be done both for weight loss and its 
maintanence. 
Avoiding sedentary leisure time activity also helps to achieve 
weight loss. 
 
ATHEROGENIC AND DIABETOGENIC DIET 
Diet low in cholesterol, saturated fatty acid, transfat, simple sugar, 
sodium with increased intake of whole grains, fruits and vegetables. 
High levels of carbohydrate can increase dyslipidemia. 25 to 30% 
of total calories is provided by fat. If fat intake is more than35% it leads 
to elevated LDL-C. But if the fat intake goes less than 25% there is 
elevation of triglycerides and decrement of HDL-C. 
Thus very low fat also worsen atherogenic lipidemia. Change in 
macronutrients can lead to weight reduction. 
High protein, low carbohydrate diet decreases weight gain because 
high protein provides satiety than carbohydrate. 
 MANAGEMENT OF METABOLIC RISK FACTORS
ELEVATED BP 
When only hypertension is present
goal of BP is less th
goal is less than130/80.
Mild BP elevation can be dealt by weight reduction exercise,
decreased sodium intake increased fresh fruit intake DASH 
DASH Eating Plan Recomendations
Antihypertensives are used to prevent long term adverse effects 
like stroke CKD, MI.
ELEVATED FASTING GLUCOSE
In patients with metabolic syndrome with IFG more than 100mg/dl 
weight reduction, exercise prevents onset of type
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 Diet. 
 
 Drug therapy 
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with metformin, Acarbose , Thiazolidanediones reduce the risk of  type II  
DM. 
 
PROTHROMBOTIC STATE 
Individuals having metabolic syndrome have elevated fibrinogen, 
plasminogen activator inhibitor-1. 
Drug therapy with LOW DOSE ASPIRIN is recommended in 
individuals with ASCVD and TypeII DM without ASCVD. 
 
PROINFLAMMATORY STATE 
Proinflammatory state is associated with metabolic syndrome 
where cytokines like TNF alpha, IL 6, fibrinogen, CRP are elevated. 
In clinical practice CRP level is the simple way to assess 
proinflammatory state. Elevated levels of CRP can be reduced by weight 
reduction. 
Drugs for treating metabolic syndrome are reported to reduce CRP. 
Example ACE inhibitors, statins, Thiazolidinediones. 
 
 
  
 
MATERIALS  
AND  
METHODS 
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MATERIALS AND METHODS 
 
Study Centre 
Institute of Internal Medicine, 
Madras Medical College and Rajiv Gandhi 
Government General Hospital,  
Chennai 
Duration of the Study 6 months April 2015 to September 2015 
Study Design Cross-sectional study 
Sample Size 100  (50-study group and 50-control group) 
Inclusion Criteria 
     Patients with Hypothyroidism (study group) as 
diagnosed by 
1. High TSH ( > 10 m IU / ml) 
2. Low FT4 ( <0.93 ng/dl) 
     Patients with euthyroidism ( control group) as 
diagnosed by 
1. Normal TSH  (0.27- 4.2 m IU / ml) 
2. Normal FT4 ( 0.93-1.7 ng/dl ) 
 
Exclusion Criteria 
 
1. Patients with known hypothyroidism already on 
medication 
2. Patients with hyperthyroidism and subclinical 
hyperthyroidism 
3. Patients under treatment for any thyroid related 
disorder 
4. Patients with liver disorder, renal disorder, 
congestive cardiac failure, pregnant women. 
5. patients on OCP, statins and other medications 
that alter thyroid functions 
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IDF 
Criteria for metabolic 
syndrome  
 
 
 
 
 
 
1. Central or abdominal obesity (measured by 
waist    circumference :)in men > 102cms  and in 
women >88 cms    
PLUS any two of the following four factors: 
2. Triglycerides > or equal to 150 mg/dl 
3. HDL Cholesterol: men < 40 mg/dl, women <50 
mg/dl 
4. Blood pressure > or equal to 130/ 85 mmHg or 
on anti-hypertensives 
5. Fasting glucose > or equal to 100 mg/dl or on 
anti-diabetic drugs 
 
Ethical committee 
approval obtained 
Data Collection and 
Methods 
Patients are subjected to detailed history taking and 
clinical examination. 
           Consent  Written informed consent obtained 
Methodology 
(Materials and 
Methods) 
 
Patients newly diagnosed with hypothyroidism based 
on above said criteria are subjected to screening for 
metabolic syndrome 
 
Product / Procedure / 
Investigation Details 
1. Thyroid function tests 
2. Fasting plasma glucose 
3. Serum lipid profile 
4. BP record 
5. Anthropometric tests ( height, weight, BMI , 
waist circumference) 
Sponsorship (Yes/ No) 
If Yes details No 
Analysis plan 
Analysis was done using SPSS Version 20. 
Significance was assumed with a p value of 0.05. 
Association between two categorical variables was 
done using chi square test. All p values were two tailed 
and significant when values were less than 0.05. 
Conflict of interest No  
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OBSERVATION AND RESULTS 
                  In our study comprising of 100 members, 50 belong to control 
group (euthyroid) and 50 belong to study group (hypothyroid). It is 
observed that 21 have metabolic syndrome in which 6 belong to control 
group and 15 belong to study group with distribution % of  28.6 and 71.4 
respectively. 
 
There is significant correlation in the occurrence of metabolic 
syndrome between the control (euthyroid) and study (hypothyroid) 
groups, with p value of 0.048. 
 
IDF CRIT.
NoYes
Co
u
n
t
50
40
30
20
10
0
Group
Control
Cases
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COMPARISON OF THE INCIDENCE OF METABOLIC 
SYNDROME IN HYPOTHYROID AND EUTHYROID GROUPS 
 
  Group Total 
  Control Cases  
IDF CRIT. Yes Count 6 15 21 
  % within IDF CRIT. 28.6% 71.4% 100.0% 
  % within Group 12.0% 30.0% 21.0% 
 No Count 44 35 79 
  % within IDF CRIT. 55.7% 44.3% 100.0% 
  % within Group 88.0% 70.0% 79.0% 
Total Count 50 50 100 
 % within IDF CRIT. 50.0% 50.0% 100.0% 
 % within Group 100.0% 100.0% 100.0% 
 
 
This table shows that the incidence of metabolic syndrome in the 
hypothyroid and euthyroid groups are 71.4 % and 28.6 % respectively, 
indicating that metabolic syndrome is more common among hypothyroid 
group 
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TABLE SHOWING CORRELATION OF INCIDENCE OF 
METABOLIC SYNDROME IN HYPOTHYROID AND 
EUTHYROID GROUPS 
 
 Value Df Asymp. Sig.  (2-sided) 
Exact Sig.  
(2-sided) 
Exact Sig.  
(1-sided) 
 
Pearson Chi-Square 4.882(b) 1 .027   
 
Continuity 
Correction(a) 
3.858 1 .050   
 
Likelihood Ratio 5.012 1 .025   
 
Fisher's Exact Test    .048 .024 
 
Linear-by-Linear 
Association 
4.834 1 .028   
 
N of Valid Cases 100     
 
 
This table shows that the p value is significant , implying that there 
is a higher incidence of metabolic syndrome in hypothyroid patients. 
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SEX:   
Among 21 members with metabolic syndrome 13 are female and 8 
are male .In female 4 are from control group and 9 are from study group 
with 61.9% incidence found in female. Among  male 2 are from control 
group and 6 from study group with 38.1% incidence in male. 
 
 
          There is  no significant  correlation  in the incidence of Mets 
between the control (euthyroid) and study (hypothyroid) groups in view 
of sex, with p value of  1.00 in control and 0.765 in study group. 
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AGE:    
Among 21 members with metabolic syndrome ,13 are above the 
age of 40 and 8 are below the age of 40. In 13,about 10 are from study 
group and 3 are from  control group with 61.9% distribution. Among 
those 8 members below age of 40, about 5 are from study group and 3 are 
from control group with distribution of 38.1%. 
 
 
On the basis of age difference, there is no significant  correlation  
between the control  and study  groups , with p value of  0.686 in control 
and 0.217 in study group for Mets 
Group=Control
IDF CRIT.
NoYes
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u
n
t
30
20
10
0
Age in years
<= 40
> 40
Group=Cases
IDF CRIT.
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30
20
10
0
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TGL:  
Among 100 members ,65 have TGL less than 150 mg/dl. In these 
65 members 24 belong to study group and 41 belong to control group 
with 36.9% and 63.1% respectively. Remaining 35 members have TGL  
more than 150mg/dl. Among these 26 belong to study group and 9 from 
control group with distribution of 74.3% and 25.7 %respectively. 
 
         In view of TGL values, correlation is significant between control 
and study group. P value is 0.001. 
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> 150< 150
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TABLE SHOWING THE DISTRIBUTION OF TRIGLYCERIDE 
LEVELS IN HYPOTHYROID AND EUTHYROID GROUPS 
  
Group 
Total Control Cases 
TGL 
    < 
150 
mg/
dl 
Count 41 24 65 
% within 
TGL 
63.1% 36.9% 100.0% 
% within 
Group 
82.0% 48.0% 65.0% 
> 
150 
mg/
dl 
Count 9 26 35 
% within 
TGL 
25.7% 74.3% 100.0% 
% within 
Group 
18.0% 52.0% 35.0% 
Total 
Count 50 50 100 
% within 
TGL 
50.0% 50.0% 100.0% 
% within 
Group 
100.0% 100.0% 100.0% 
 
This table shows that hypothyroid group has a higher percentage of 
cases with triglyceride levels more than 150 mg/dl when compared to 
euthyroid group. (74.3% Vs 25.7%) 
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TOTAL CHOLESTEROL:  
Out of 100 members, total cholesterol is less than 200 in 69 
members, in that 29 are from study group and 40 from control group with 
distribution of 42 %and 58 % respectively. 
Out of 100, 31 members have total cholesterol more than 200. 21 
of these are from control group and 10 are from study group with 
distribution of 67.7% and 32.3% respectively. 
 
There exists significant correlation based on total cholesterol 
values between the study and control group. P value is 0.030. 
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LDL:   
Among 100 members, 58 have LDL less than 130mg/dl with 
distribution of 29.3% in study group and70.7% in control group. 
Remaining 42 members have LDL more than 130mg/dl with distribution 
of 78.6% in study group and 21.4% in control group. 
 
Correlation is found to be significant when LDL was compared 
between study and control group. P value <0.0001 
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HDL: 
65 members out of 100 have HDL less than 50mg/dl.  35member 
have HDL more than 50mg/dl. Among these 65 members  with HDL less 
than 50mg/dl,38 are from study and 27 are from control group with58.5% 
and 41.5% respectively. 
Among 35 with HDL more than50mg/dl, 12 are from study with 
34.3% and 23 are control with 65.7%. 
 
P value is 0.035 suggesting that correlation to be significant 
between the groups 
HDL
> 50< 50
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30
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BLOOD PRESSURE:  
Out of 100 ,77 members have BP <140/90 mm Hg and 23 have BP 
>140/90 mmHg. Within that 77  people,29 are from study group and 48 
are from control group with37.7% and 62.3%. respectively 
Among those with BP>140/90 mm Hg, 21 are from study and 2 are 
from control group with distribution of 91.3% and 8.7% respectively. 
 
Positive correlation is found between groups on basis of blood 
pressure with p value <0.0001 
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DISCUSSION                    
Hypothyroidism is present in about 3% of adult females .Increasing 
age is risk for hypothyroidism. Both Hypothyroidism and metabolic 
syndrome are associated with increased risk of CVD. 
                    
Thyroid hormone has significant role in various metabolic and 
developmental processes in our body. The effects of Thyroid hormones 
are stimulation of  BMR, increased energy expenditure through increased 
ATP utility, and increased responsiveness through catecholamines by 
modulating adrenergic receptors. It also upregulates GLUT-4 in skeletal 
muscle and adipose tissue there by leading to lipolysis. Thus thyroid 
hormone has influence on lipid metabolism also. 
                    
Decreased thyroid level also leads to increase in TG’s due to 
decreased activity of TG lipase from liver and there by reducing the 
clearance of TGs from plasma. There is significant overlap between CVS 
risk factors  and effects of hypothyroidism like increased stiffness of 
arteries, elevated blood pressure, endothelial dysfunction and diastolic 
dysfunction.  
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The number of thyroid hormone receptors are decreased  in persons 
with obesity. There is also association between insulin resistance and 
hypothyroidism both of which contributes to the development of 
metabolic syndrome. 
 
Thus metabolic syndrome on the whole is the constellation of risk 
factors interrelated with risk factor or CVD, Type II DM, 
Hypercholesterolemia. 
                      
In Indian Journal 0f  Endocrinology and Metabolism, The study 
conducted on  “The Metabolic Syndrome in Thyroid Disease from 
Nigeria by Anthonia et al(71). The study concluded that 1 in every 25 (i.e) 
25% with Thyroid disorder have metabolic syndrome. 
 
Our study also reveals that 30% of persons with thyroid disorder 
have metabolic syndrome. 
 
The study on Age and Sex Differences in the clustering of 
metabolic syndrome factors by Jennifer L Kuk et al(72) concluded that 
incidence of metabolic syndrome increases with Age and also more 
common in Female.  
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            In our study 61.9% of members with metabolic syndrome  are 
above the age of 40 years and 38.1% are below 40 years. Also 61.9% of 
individuals with METs are female and 38.1% are male. 
 
The study of  ”Effects of Hypothyroidism as a cause of 
Hypertension” by Saito I, Ito K et al(73)  concludes that in hypothyroidism 
14.8% has BP>160/95 mm Hg compared toEuthyroid individuals in 
which 5.5% have BP<160/95mmHg. 
 
           In our study, among study group out of 50,21 have BP>140/90 
mm Hg and in control group of 50 members ,2 have BP >140/90 mmHg.  
                  
           The study of effects of thyroid disorder on lipid profile concludes 
that by Rizoz et al(74). concludes that high TSH value increases total 
cholesterol, TGL, LDL nad decreases the HDL.  
                  
Two Chinese studies conducted on association between TSH level 
and total cholesterol by wang F et al(75), wanjia X et al(76) concluded that 
high TSH level independent of thyroid hormone level leads to elevated 
total cholesterol. 
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The Hunt(77) study, which is a population based study for 
association between TSH level and lipid profile arrived at significant (p 
for trend <0.001) linear increase in cholesterol, LDL, TGL levels with 
TSH levels and linear decrease (p for trend<0.001) in HDL 
cholesterolwith increase in TSH levels. 
 
Our study also exhibits linear relationship between increase in TSH 
levels with increase in total cholesterol (p value 0.030),  LDL ( p vale 
<0.001), TGL (p value 0.001) and decrease in HDL (p value 0.035) 
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CONCLUSION 
• Metabolic syndrome is more prevalent in Hypothyroid patients 
compared to Euthyroid individual 
 
• Metabolic syndrome is more common in Female than Male as in 
hypothyroidism in which higher incidence is found in Female. 
 
• Incidence of Metabolic syndrome increases with advancing Age. 
 
• Thyroid stimulating hormone value in hypothyroidism has positive 
correlation with increase in Total cholesterol, Low Densty 
Lipoprotein and Triglycerides. It also has negatively correlation  
with HDL level. 
 
• Hypothyroidism shows significant increase in Blood pressure 
compared to Euthyroid state.  
 
• It suggests that there exists  positive correlation  between 
hypothyroidism and metabolic syndrome. 
 
• Both Metabolic syndrome and Hypothyroidism increases the risk 
of Cardiovascular Disease. There is significant overlap in the 
pathogenesis and risk factors of  Metabolic syndrome and 
Hypothyroidism. 
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• Early screening of Hypothyroidism in Metabolic syndrome and the 
vice versa, along with screening of other risk factors for 
Cardiovascular disease ,for early intervention will lead to 
significant reduction in Cardiovascular morbidity and mortality. 
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LIMITATIONS 
 
The presence and absence of confounding factors and diseases that 
influence the metabolic and thyroid parameters are not subjected for 
analysis in the study. 
 
Sample included is limited involving 100 subjects. 
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ANNEXURES 
  
PROFORMA 
“STUDY ON THE PREVALENCE OF METABOLIC 
SYNDROME IN THE NEWLY DIAGNOSED  
HYPOTHYROID PATIENTS” 
 
Name:    Age/Sex:                      Patient ID: 
Address:                                         Occupation: 
 
CLINICAL DETAILS: 
 
PAST HISTORY: if present ,duration and treatment details. 
TYPE 2 DM  
SYSTEMIC HYPERTENSION  
DYSLIPIDEMIA  
CLD  
TUBERCULOSIS  
CKD  
CORONARY HEART DISEASE  
CEREBROVASCULAR ACCIDENT  
 
PERSONAL HISTORY: 
H/o smoking 
H/o alcohol 
General physical examination:                                 Head to toe 
examination: 
Pallor – 
Icterus –  
Cyanosis – 
Clubbing –  
Generalized lymphadenopathy –  
Pedal edema –  
Height -  
Weight –  
BMI –  
Waist ratio –  
VITALS 
PR –  
BP – 
Temperature – 
SYSTEMIC  EXAMINATION: 
 
CVS: 
RS: 
 
ABDOMEN: 
 
CNS: 
INVESTIGATIONS: 
THYROID PROFILE: 
FREE T3 
FREE T4 
TSH 
COMPLETE HEMOGRAM  
HEMOGLOBIN – 
TOTAL COUNT – 
DIFFERENTIAL COUNT – 
RBC COUNT – 
PLATELETS – 
RENAL FUNCTION 
SERUM CREATININE – 
BLOOD UREA 
LIVER FUNCTION TESTS  
TOTAL BILIRUBIN – 
ENZYMES -       OT  -        PT -        ALP -    
TOTAL PROTEIN -  
SERUM ALBUMIN - 
FASTING PLASMA GLUCOSE –  
SERUM LIPID PROFILE – 
TOTAL CHOLESTEROL –  
LDL – 
HDL – 
TRIGLYCERIDES                                   
                         

INFORMATION SHEET 
We are conducting a “STUDY ON THE PREVALENCE OF 
METABOLIC SYNDROME IN THE NEWLY DIAGNOSED  
HYPOTHYROID PATIENTS” among patients attending Rajiv Gandhi 
Government General Hospital, Chennai and for that your specimen may 
be valuable to us. 
           The purpose of this study is to compare the prevalence of 
metabolic syndrome in newly diagnosed hypothyroid patients with that of 
euthyroid cases and to aid in early screening and prevent the 
complications of metabolic syndrome in hypothyroid patients. 
We are selecting certain cases and if you are found eligible, we 
may be using your blood samples to do certain tests which in any way do 
not affect your final report or management. 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. 
Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
 
Signature of Investigator    Signature of Participant 
 
Date: 
Place: 

PATIENT CONSENT FORM 
Study Detail : 
 “STUDY ON THE PREVALENCE OF METABOLIC 
SYNDROME IN THE NEWLY DIAGNOSED 
HYPOTHYROID PATIENT”   
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction. 
❏ 
b) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected. 
❏ 
c) I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will 
not need my permission to look at my health records, both in respect of 
current study and any further research that may be conducted in relation 
to it, even if I withdraw from the study I agree to this access. However, I 
understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this 
study. 
❏ 
d) I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and 
to immediately inform the study staff if I suffer from any deterioration in 
my health or well being or any unexpected or unusual symptoms. 
❏ 
e) I hereby consent to participate in this study. ❏ 
f) I hereby give permission to undergo detailed clinical examination and 
blood investigations as required. 
❏ 
 
Signature / thumb impression:   Signature of Investigator 
 
Patient’s Name and Address:    Study Investigator’s Name: 
 
  
 
PLAGIARISM SCREEN SHOT 
 
 
 
 
 
 
 
 
 
  
   
  
 
 
 
 
MASTER CHART 
 
CONTROL GROUP 
SNO AGE SEX TSH FREE  T4 W.C T.C TGL HDL LDL BP FBS 
IDF 
CRIT. 
1 13 F 3 .0 1.1 81 145 110 48 100 110/80 85 NO 
2 21 F 0.4 1.6 89 158 131 56 98 120/70 100 NO 
3 29 F 2.5 0.9 78 125 115 51 129 108/80 90 NO 
4 18 F 1.9 1.1 83 190 119 39 115 120/72 107 NO 
5 39 F 3.5 1.5 115 198 153 51 118 140/90 120 YES 
6 28 F 4.1 1.1 79 123 132 48 110 110/82 105 NO 
7 34 F 0.9 0.9 78 200 130 55 129 106/68 170 NO 
8 26 F 3.5 1.3 89 119 110 43 100 120/80 93 NO 
9 38 F 1.9 1.6 84 208 115 56 119 128/80 103 NO 
10 23 F 0.8 1.5 110 148 134 51 128 124/74 81 NO 
11 18 F 3.4 1.3 69 109 98 58 117 104/64 101 NO 
12 39 F 2.7 1.7 79 150 109 59 129 100/80 105 NO 
13 31 F 4.2 1.0 109 201 159 38 132 126/90 100 YES 
14 28 F 0.5 1.6 88 168 139 48 100 130/72 99 NO 
15 26 F 0.9 1.1 83 191 98 59 109 122/84 109 NO 
16 34 F 3.4 1.7 91 120 210 51 126 124/70 99 NO 
17 30 F 2.9 1.2 82 115 123 58 121 110/70 110 NO 
18 40 F 4.1 1.5 78 148 125 50 99 108/86 106 NO 
19 48 F 0.3 1.2 79 191 101 47 97 110/74 76 NO 
20 51 F 3.8 0.9 80 115 100 38 118 132/80 120 NO 
21 66 F 2.2 1.6 99 165 185 51 132 148/92 101 YES 
22 70 F 0.7 1.2 90 185 130 56 160 132/80 91 NO 
23 45 F 3.7 1.4 89 109 128 49 129 120/82 99 NO 
24 50 F 1.8 1.6 85 210 85 50 126 110/72 117 NO 
25 58 F 1.3 1.0 83 120 119 53 148 150/100 79 NO 
26 47 F 2.8 1.5 79 98 145 43 117 132/80 78 NO 
27 54 F 1.0 1.2 80 109 121 49 100 120/78 85 NO 
28 61 F 3.6 1.4 105 260 171 36 139 140/90 80 YES 
29 70 F 2.6 1.6 78 141 135 41 145 108/98 105 NO 
30 17 M 1.1 1.0 75 136 137 49 109 136/70 78 NO 
31 23 M 0.8 1.3 100 196 121 45 127 120/80 115 NO 
32 31 M 3.5 1.5 80 208 148 53 119 134/92 120 NO 
33 28 M 2.9 1.0 79 151 109 48 98 110/70 72 NO 
34 21 M 1.2 0.9 78 175 132 46 100 120/70 100 NO 
35 36 M 4.1 1.7 87 138 144 54 121 132/82 78 NO 
36 39 M 4.0 1.1 110 169 164 53 195 130/80 135 YES 
37 26 M 1.9 1.6 108 119 131 57 109 126/70 98 NO 
38 25 M 2.4 1.7 78 108 148 68 119 120/82 96 NO 
39 38 M 1.9 0.9 79 136 101 48 128 130/70 85 NO 
40 40 M 3.2 1.4 80 148 140 48 110 122/86 110 NO 
41 45 M 1.7 1.6 69 168 120 51 120 136/72 120 NO 
42 51 M 3.9 1.1 71 220 131 50 121 136/84 110 NO 
43 59 M 1.3 1.3 74 209 120 53 115 130/82 78 NO 
44 61 M 0.9 1.6 80 110 99 48 151 126/74 98 NO 
45 42 M 1.3 1.3 75 250 157 56 128 134/94 105 NO 
46 68 M 1.6 1.7 71 270 175 48 108 120/92 123 NO 
47 70 M 2.8 1.0 109 198 200 35 138 126/70 117 YES 
48 59 M 4.2 1.2 72 151 111 45 119 130/84 88 NO 
49 43 M 0.5 1.5 80 149 135 49 109 108/70 95 NO 
50 62 M 0.9 1.3 91 290 128 53 121 130/108 105 NO 
 
 
 
 
 
  
STUDY GROUP (HYPOTHYROID) 
SNO AGE SEX TSH 
FREE  
T4 
W.C T.C TGL HDL LDL BP FBS 
IDF 
CRIT. 
1 18 F 14.1 0.5 75 178 148 40 156 132/84 97 NO 
2 29 F 12.6 0.3 81 210 145 39 140 134/98 70 NO 
3 35 F 18.5 0.09 95 150 248 36 178 140/90 88 YES 
4 37 F 25.1 0.03 90 185 131 42 191 96/62 85 NO 
5 34 F 29.0 0.05 80 191 260 49 121 122/78 99 NO 
6 34 F 18.1 0.3 78 138 128 51 127 110/82 81 NO 
7 26 F 15.2 0.4 79 145 148 38 109 92/78 99 NO 
8 29 F 30.1 0.07 90 268 198 46 138 140/94 110 YES 
9 39 F 28.6 0.2 100 268 148 53 119 112/74 105 YES 
10 28 F 35.2 0.08 85 218 178 54 181 106/60 99 NO 
11 37 F 18.9 0.2 79 191 220 40 193 162/110 126 NO 
12 31 F 15.0 0.4 80 178 195 56 161 140/94 115 NO 
13 25 F 21.9 0.06 85 188 198 47 129 122/82 109 NO 
14 40 F 45.3 0.2 80 319 115 58 121 120/70 105 NO 
15 58 F 29.0 0.08 101 195 148 35 165 136/80 167 YES 
16 51 F 60.1 0.3 79 298 131 55 161 180/118 98 NO 
17 49 F 51.0 0.01 110 185 198 51 139 190/110 128 YES 
18 71 F 28.3 0.1 85 265 230 53 210 160/108 88 NO 
19 65 F 18.7 0.2 93 160 169 38 178 152/96 90 YES 
20 62 F 12.5 0.3 102 151 145 53 128 186/102 98 NO 
21 58 F 15.1 0.1 104 138 149 32 158 134/80 115 YES 
22 45 F 25.0 0.7 80 278 158 57 199 120/70 109 NO 
23 48 F 36.3 0.03 78 216 139 40 151 136/74 88 NO 
24 63 F 40.1 0.6 95 178 159 51 168 134/80 115 YES 
25 58 F 20.9 0.05 81 310 270 48 151 164/112 100 NO 
26 49 F 15.8 0.1 85 215 120 48 120 130/86 99 NO 
27 60 F 14.3 0.8 89 140 198 49 210 142/92 125 YES 
28 62 F 98.1 0.3 83 240 134 46 198 120/80 89 NO 
29 20 M 18.5 0.6 90 265 185 34 119 142/90 115 NO 
30 28 M 40.0 0.09 97 178 119 40 197 130/82 125 NO 
31 39 M 50.3 0.01 109 138 145 42 160 136/82 119 YES 
32 31 M 82.3 0.2 85 230 133 41 178 142/80 89 NO 
33 27 M 17.9 0.05 79 185 141 48 109 140/76 105 NO 
34 29 M 12.0 0.7 91 191 220 43 98 126/82 101 NO 
35 35 M 19.7 0.6 99 178 138 46 121 160/110 98 NO 
36 38 M 21.3 0.2 111 180 290 51 210 164/110 150 YES 
37 33 M 11.9 0.8 100 145 175 47 117 136/70 98 NO 
38 38 M 15.3 0.4 95 218 198 49 197 140/84 105 NO 
39 40 M 29.8 0.7 89 185 120 43 123 168/108 120 NO 
40 51 M 71.4 0.5 108 138 210 48 195 132/90 210 YES 
41 49 M 58.2 0.1 97 220 119 34 170 122/70 96 NO 
42 60 M 34.9 0.3 101 278 178 41 127 160/112 170 NO 
43 68 M 22.3 0.5 80 251 117 39 220 174/110 120 NO 
44 49 M 19.0 0.2 89 210 195 41 97 200/120 105 NO 
45 54 M 105.8 0.2 118 178 220 43 160 130/92 145 YES 
46 58 M 20.1 0.8 108 193 121 48 148 120/80 95 NO 
47 45 M 13.2 0.1 85 291 270 41 109 134/88 160 NO 
48 65 M 17.1 0.7 119 148 139 50 198 168/102 138 YES 
49 51 M 51.0 0.2 100 210 199 39 169 196/118 121 NO 
50 59 M 42.8 0.3 107 165 188 34 139 152/110 138 YES 
 
 KEY TO MASTER CHART 
S.NO. -  Serial Number 
TSH  -  Thyroid Stimulating Hormone 
WC  -  Waist Circumference 
TC  -  Total Cholesterol 
TGL  -  Triglycerides 
HDL  -  High Density Lipoprotein 
LDL  -  Low Density Lipoprotein 
BP  -  Blood Pressure 
FBS  -  Fasting Blood Glucose 
IDF CRIT - International Diabetes Federation 
M  -  Male 
F  -  Female 
